Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction is currently active. With a performance of 6.12%, the BUY prediction by Global_Player for Esperion Therapeutis.Inc. is trending in the right direction. This prediction currently runs until 29.08.26. The prediction end date can be changed by Global_Player at any time. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | 6.12% |
iShares Core DAX® | -2.458% |
iShares Nasdaq 100 | -1.226% |
iShares Nikkei 225® | -1.984% |
iShares S&P 500 | -0.767% |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21